Nykode Therapeutics AS reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was USD 2.19 million compared to USD 2.69 million a year ago. Revenue was USD 2.28 million compared to USD 3.3 million a year ago.

Net loss was USD 5.34 million compared to USD 12.21 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.04 a year ago. Diluted loss per share from continuing operations was USD 0.02 compared to USD 0.04 a year ago.